Nexalin Technology Announces Regulatory Approval Of Gen-2 15mA Neurostimulation Device By Brazilian Health Regulatory Agency
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has received regulatory approval from the Brazilian Health Regulatory Agency for its Gen-2 15mA neurostimulation device.
June 13, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology has received regulatory approval from the Brazilian Health Regulatory Agency for its Gen-2 15mA neurostimulation device. This approval could open up new market opportunities in Brazil, potentially boosting the company's revenues and market presence.
The regulatory approval in Brazil is a significant milestone for Nexalin Technology as it allows the company to enter a new market. This could lead to increased sales and revenue, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100